Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
TORONTO--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., is proud to announce that it has been named to Forbes list of Canada’s Best Employers 2024. Teva Canada ranked No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers.
Forbes and market research firm, Statista Inc. selected Canada’s Best Employers 2024 by conducting independent surveys of over 40,000 Canada-based employees from companies employing at least 500 people in all industry sectors. Over 900,000 employer evaluations were considered. Full methodology available here.
“We’re honoured to be recognized by Forbes and our employees as the No. 1 employer in the Canadian Drugs & Biotechnology industry,” stated Michael Sine, General Manager, Teva Canada. “It’s no secret that our employees are our greatest asset. This recognition reflects the pride our employees feel about working at Teva Canada. Their passion to show up each day and never lose sight of the human connection to the patients we serve is remarkable; we intend to keep cultivating an environment where employees can thrive.”
Being recognized as one of Canada’s Best Employers 2024 highlights the importance of Teva Canada’s Core Values which provide the framework for its workplace culture.
“Our people define our culture, and our Human Resources programs strive to enhance engagement and wellbeing while allowing employees to realize professional and personal ambitions,” added Anthony Primiani, Senior Director, Human Resources, Teva Canada. “We practice deliberate listening which leads to key programs that enhance the work-life balance, such as paid time to volunteer with their charity of choice, flexibility and income replacement for those managing illness or caring for a loved one.”
The awards list was announced on January 23, 2024 and the full list of Canada’s Best Employers 2024 can be viewed here.
About Teva Canada
Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for nearly 60 years, with more than 164,0001 prescriptions filled each day with our products, representing 1 of every 8 generic prescriptions in Canada2. Originally Novopharm Limited, Teva Canada specializes in the development, production, and marketing of high-quality generic prescription pharmaceuticals that generated over $1.74 billion3 in Canadian healthcare savings in 2022 and, through our branded division, focuses on a diverse line of specialty and biopharmaceutical products in a variety of therapeutic areas such as central nervous system (CNS), respiratory, oncology and rheumatology. Teva Canada’s commitment to helping improve the lives of Canadians extends to the Teva Caregiver Program - providing tools and resources for Canadians navigating the care journey as well as numerous Patient Support and Health Care Professional Programs. Awarded by Forbes as Canada’s Best Employer 2024 in the Drugs & Biotechnology sector (and No. 28 of 300 overall employers), Teva Canada employs more than 900 passionate people and markets nearly 3004 medicines in Canada. We are a proud subsidiary of Teva Pharmaceutical Industries Ltd. Learn more at www.tevacanada.com.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
1 | Source: IQVIA CDH Compuscript TRx MAT February 2023 |
2 | Source: IQVIA Compuscript Trx MAT 2020.12 |
3 | Sources: Dylst P, Vulto A, Simoens S. Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):701-11; Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy. 2013 Oct;11(5):437-43; https://canadiangenerics.ca/ |
4 | Source: Teva Price list January 8, 2024 |
Contacts
IR Contacts
United States
Ran Meir (267) 638-8167
Israel
Yael Ashman 972 (3) 914-8262
PR Contacts
Canada / International
Teva Canada Public Affairs public.affairs@tevacanada.com
Editor Details
-
Company:
- Businesswire
